Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Rigel Pharmaceuticals Inc. Stories

2010-06-03 06:30:00

SOUTH SAN FRANCISCO, Calif., June 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Ryan Maynard, executive vice president and chief financial officer of Rigel, will present at three separate investor conferences in June. Details of each conference are as follows: Jefferies Global Life Sciences Conference New York City, NY June 10, 8:00 a.m. EST Speaker: James M. Gower...

2010-06-01 06:30:00

SOUTH SAN FRANCISCO, Calif., June 1 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the promotion of three members of senior management, effective immediately. Raul R. Rodriguez has been named president in addition to his position of chief operating officer; Dolly Vance assumes the title general counsel and executive vice president of Corporate Affairs; and Ryan Maynard is executive vice president and chief financial officer. Each of them has been a...

2010-05-04 06:30:00

SOUTH SAN FRANCISCO, Calif., May 4 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2010. For the first quarter of 2010, Rigel reported a net loss of $22.3 million, or $0.43 per share, compared to a net loss of $29.9 million, or $0.82 per share, in the first quarter of 2009. Weighted average shares outstanding for the first quarters of 2010 and 2009 were 52.0 million and 36.7 million, respectively....

2010-04-30 06:30:00

SOUTH SAN FRANCISCO, Calif., April 30 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) has been named one of the recipients of the 2010 Innovators Award of Excellence by the San Mateo County Economic Development Association (SAMCEDA). The award will be presented at the association's Innovators luncheon today at the Oracle Conference Center in Redwood City. Donald G. Payan, Rigel's co-founder, executive vice president and president of Discovery and Research will accept...

2010-03-18 06:30:00

SOUTH SAN FRANCISCO, Calif., March 18 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will provide a live webcast for its Investor Day on March 25, 2010 at 10:00am EDT. Members of Rigel's senior management team will provide an overview of the company's current product pipeline. The event will be webcast live and can be accessed from Rigel's website at www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the...

2010-03-17 06:30:00

SOUTH SAN FRANCISCO, Calif., March 17 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Barclays Capital 2010 Global Healthcare Conference in Miami, Florida on Tuesday, March 23 at 10:45 a.m. EDT. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several...

2010-03-05 06:30:00

SOUTH SAN FRANCISCO, Calif., March 5 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Cowen and Company 30th Annual Health Care Conference in Boston, Massachusetts on Tuesday, March 9th at 3:45 p.m. EST. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website...

2010-03-02 06:00:00

SOUTH SAN FRANCISCO, Calif., March 2 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and year ended December 31, 2009. For the fourth quarter of 2009, Rigel reported a net loss of $25.1 million, or $0.48 per share, compared to a net loss of $33.4 million, or $0.91 per share, in the fourth quarter of 2008. Weighted average shares outstanding for the fourth quarters of 2009 and 2008 were 51.8 million and 36.6...

2010-02-16 01:01:00

SOUTH SAN FRANCISCO, Calif., Feb. 16 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that its senior management team will host a conference call, and simultaneous audio webcast, today at 8:30 a.m. EST (5:30 a.m. PST) to discuss its partnership with AstraZeneca for Rigel's late-stage investigational product, fostamatinib disodium (R788), for the treatment of rheumatoid arthritis and additional indications. Conference Call and Webcast Information To access the...

2010-02-16 01:00:00

SOUTH SAN FRANCISCO, Calif., Feb. 16 /PRNewswire-FirstCall/ -- AstraZeneca and Rigel Pharmaceuticals (Nasdaq: RIGL) today announced an exclusive worldwide license agreement for the global development and commercialization of fostamatinib disodium (R788), Rigel's late-stage investigational product for rheumatoid arthritis (RA) and additional indications. Fostamatinib disodium, which has completed a comprehensive phase 2 program, is the furthest developed oral Spleen Tyrosine Kinase (Syk)...